logo
  • Home
  • News
Menu

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

Home / Stock Analysis / EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®
Article feature image

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

20 Jul Stock Analysis

WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced…

Click here to view the original article.

Tags:
Global, Yahoo Entertainment
Facebook Google+ Twitter Pinterest
  Previous
Next  

Related Posts

ON20Semiconductor20Corp_20sign20in20Silicon20Valley-by20Sundry20Photography20via20Shutters.jpeg
+

What Are Wall Street Analysts’ Target Price for ON Semiconductor Stock?

03 Nov Stock Analysis
1762180540_articleshow.jpg
+

kenvue: Kenvue stock share price today: Kimberly-Clark to acquire Tylenol maker Kenvue for $40 billion in cash and stock deal. Here’s background, current challenges, future outlook, market reaction

03 Nov Stock Analysis

recent post

  • ON20Semiconductor20Corp_20sign20in20Silicon20Valley-by20Sundry20Photography20via20Shutters.jpeg

    What Are Wall Street Analysts’ Target

    Nov 03 2025
  • shutterstock_770928181-1002x333.jpg

    Fidelity launches first crypto asset for

    Nov 03 2025
  • 1762180540_articleshow.jpg

    kenvue: Kenvue stock share price today:

    Nov 03 2025
  • Binance_Market_Shaer.jpg

    $7B Inflow Signals Crypto Market Upswing

    Nov 03 2025
  • 1585186660639.jpeg

    Newton Resources Ltd’s (HKG:1231) stock price

    Nov 03 2025

Categories

  • Business
  • Crypto News
  • Investing Strategy
  • People
  • Stock Analysis

©2019.  All Rights Reserved.